Abstract

Reconsidering the Use of Propranolol in the Treatment of Cosmetic Infantile Hemangiomas

Highlights

  • Up to 10% of infants are stricken with benign vascular tumors commonly referred to as strawberry marks and clinically defined as Infantile Hemangiomas (IHs)

  • The beta blocker propranolol has been utilized as the gold standard of treatment against IHs, with an efficacy rate of close to 95%

  • Data published by Slotkin et al [11] suggest that regulation of beta adrenergic signaling in the developing brain differs substantially from the homeostatic mechanisms seen in maturity, and that beta blockade in the neonate induces heterologous sensitization leading to sustained and enhanced responses to the treatment

Read more

Summary

Introduction

Up to 10% of infants ( females) are stricken with benign vascular tumors commonly referred to as strawberry marks and clinically defined as Infantile Hemangiomas (IHs). More and more vascular anomaly centers are using propranolol with great success and generally good control over acute side effects, little discussion has been put forth regarding the long term side effects of systemic beta blockade in developing children.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.